411 related articles for article (PubMed ID: 28778687)
21. Immunotherapy for Chronic Hepatitis B Virus Infection.
Bertoletti A; Le Bert N
Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747
[TBL] [Abstract][Full Text] [Related]
22. New antivirals for the treatment of chronic hepatitis B.
Soriano V; Barreiro P; Benitez L; Peña JM; de Mendoza C
Expert Opin Investig Drugs; 2017 Jul; 26(7):843-851. PubMed ID: 28521532
[TBL] [Abstract][Full Text] [Related]
23. [New Potential Therapies for Chronic Hepatitis B].
Yoo SH; Kwon JH
Korean J Gastroenterol; 2019 Nov; 74(5):267-273. PubMed ID: 31765555
[TBL] [Abstract][Full Text] [Related]
24. New therapies for chronic hepatitis B.
Bitton Alaluf M; Shlomai A
Liver Int; 2016 Jun; 36(6):775-82. PubMed ID: 26854115
[TBL] [Abstract][Full Text] [Related]
25. Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies.
Degasperi E; Anolli MP; Lampertico P
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366502
[TBL] [Abstract][Full Text] [Related]
26. Updates in the management of hepatitis B in children.
Lai MW; Chang MH
Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1065-1076. PubMed ID: 31663387
[No Abstract] [Full Text] [Related]
27. Chronic hepatitis B: what should be the goal for new therapies?
Block TM; Gish R; Guo H; Mehta A; Cuconati A; Thomas London W; Guo JT
Antiviral Res; 2013 Apr; 98(1):27-34. PubMed ID: 23391846
[TBL] [Abstract][Full Text] [Related]
28. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
[TBL] [Abstract][Full Text] [Related]
30. Toward Elimination of Hepatitis B Virus Using Novel Drugs, Approaches, and Combined Modalities.
Boucle S; Bassit L; Ehteshami M; Schinazi RF
Clin Liver Dis; 2016 Nov; 20(4):737-749. PubMed ID: 27742011
[TBL] [Abstract][Full Text] [Related]
31. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
[TBL] [Abstract][Full Text] [Related]
32. Antibody-mediated immunotherapy against chronic hepatitis B virus infection.
Gao Y; Zhang TY; Yuan Q; Xia NS
Hum Vaccin Immunother; 2017 Aug; 13(8):1768-1773. PubMed ID: 28521640
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus-host interactions and novel targets for viral cure.
Ligat G; Verrier ER; Nassal M; Baumert TF
Curr Opin Virol; 2021 Aug; 49():41-51. PubMed ID: 34029994
[TBL] [Abstract][Full Text] [Related]
34. Clinical Trial Design for Immune-Based Therapy of Hepatitis B Virus.
Gill US; Bertoletti A
Semin Liver Dis; 2017 May; 37(2):85-94. PubMed ID: 28564718
[TBL] [Abstract][Full Text] [Related]
35. Aiming for cure in HBV and HDV infection.
Petersen J; Thompson AJ; Levrero M
J Hepatol; 2016 Oct; 65(4):835-848. PubMed ID: 27270043
[TBL] [Abstract][Full Text] [Related]
36. Drugs in Development for Hepatitis B.
Dawood A; Abdul Basit S; Jayaraj M; Gish RG
Drugs; 2017 Aug; 77(12):1263-1280. PubMed ID: 28660478
[TBL] [Abstract][Full Text] [Related]
37. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
38. HBV cure: why, how, when?
Levrero M; Testoni B; Zoulim F
Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
[TBL] [Abstract][Full Text] [Related]
39. Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure.
Walsh R; Hammond R; Yuen L; Deerain J; O'Donnell T; Leary T; Cloherty G; Gaggar A; Kitrinos K; Subramanian M; Wong D; Locarnini S
Liver Int; 2019 Nov; 39(11):2066-2076. PubMed ID: 31379058
[TBL] [Abstract][Full Text] [Related]
40. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
Lin CL; Kao JH
Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
